Programmed Death-Ligand 1 Tumor Proportion Score and Overall Survival From First-Line Pembrolizumab in Patients With Nonsquamous Versus Squamous NSCLC
Deborah B. Doroshow, Wei Wei, Swati Gupta, Jon Zugazagoitia, Charles T. Robbins, Blythe Adamson, David L. Rimm
Topics & Concepts
MedicinePembrolizumabOncologyInternal medicineOverall survivalCancerImmunotherapyCancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease PrognosisHead and Neck Cancer Studies